Bangavax Vaccine: Permission sought for clinical trial
Staff Correspondent
Staff Correspondent
The Clinical Research Organization has asked for permission to launch a clinical trial of Covid-19 vaccine Bangavax, developed by Globe Biotech Ltd of Bangladesh.
The organisation, in an application submitted to the Bangladesh Medical Research Council (BMRC) yesterday, sought to hold first and second phase clinical trials, said chief investigator of the trial Prof Mamun Al Mahtab.
Globe Biotech got permission on January 6 from the Directorate General of Drug Administration to manufacture the doses needed in a clinical trial.
If permitted, a team of 57 researchers will decide the dosage in the first phase and examine safety and efficacy in the second.